Media Coverage · April 18, 2019

Novel Antiplatelet May Offer Antithrombotic Effect Without Bleeding Risk

ACT017, a novel antiplatelet agent, has consistent pharmacokinetic and pharmacodynamic properties and appears to be safe and tolerable, according to results of a first-in-human, randomized, placebo-controlled phase 1 study.

Read full article 

Read next in 'Media Coverage'